Payment overview · 2025
General Payments
$1,113.22
46 reported records · 17 companies
Healthcare provider profile · identity verified
Laurence Ehrlich, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BOYNTON BEACH, FL · NPI 1508823402
Verified facts
What the public records show
CMS Open Payments records show Laurence Ehrlich, MD received $1,113.22 in general payments during 2025 across 46 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $318.19 | 28.6% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $149.61 | 13.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $136.82 | 12.3% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.84 | 6.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $67.03 | 6.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.39 | 5.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.29 | 4.5% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $47.53 | 4.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $41.68 | 3.7% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $30.73 | 2.8% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $28.54 | 2.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.86 | 2.1% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $23.22 | 2.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.47 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.81 | 1.4% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $15.45 | 1.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.76 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,113.22 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $169.63 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $149.61 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $133.83 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $112.96 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $67.03 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.29 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.29 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $49.61 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.61 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $47.53 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $41.68 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $30.73 | 1 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $28.54 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $26.72 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 126 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 88 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 93 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
93 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 817 | 252 |
| Amlodipine Besylate | Amlodipine Besylate | 664 | 199 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 562 | 173 |
| Losartan Potassium | Losartan Potassium | 466 | 147 |
| Metformin Hcl | Metformin Hcl | 441 | 135 |
| Alprazolam | Alprazolam | 400 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 120 |
| Lisinopril | Lisinopril | 387 | 109 |
| Omeprazole | Omeprazole | 291 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 274 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 273 | 78 |
| Ezetimibe | Ezetimibe | 227 | 83 |
| Simvastatin | Simvastatin | 216 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 174 | 32 |
| Gabapentin | Gabapentin | 158 | 59 |
| Metformin Hcl Er | Metformin Hcl | 156 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 145 | 45 |
| Carvedilol | Carvedilol | 139 | 38 |
| Eliquis | Apixaban | 126 | 37 |
| Allopurinol | Allopurinol | 124 | 37 |
| Furosemide | Furosemide | 118 | 50 |
| Tramadol Hcl | Tramadol Hcl | 114 | 26 |
| Montelukast Sodium | Montelukast Sodium | 113 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 34 |
| Ozempic | Semaglutide | 110 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 106 | 29 |
| Sertraline Hcl | Sertraline Hcl | 104 | 32 |
| Atenolol | Atenolol | 97 | 26 |
| Mounjaro | Tirzepatide | 93 | 15 |
| Clonazepam | Clonazepam | 89 | 20 |
| Farxiga | Dapagliflozin Propanediol | 88 | 23 |
| Trazodone Hcl | Trazodone Hcl | 88 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 27 |
| Famotidine | Famotidine | 85 | 28 |
| Finasteride | Finasteride | 83 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 37 |
| Jardiance | Empagliflozin | 81 | 23 |
| Amoxicillin | Amoxicillin | 79 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 23 |
| Diazepam | Diazepam | 72 | 18 |
| Donepezil Hcl | Donepezil Hcl | 72 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 22 |
| Glimepiride | Glimepiride | 69 | 20 |
| Valsartan | Valsartan | 66 | 24 |
| Prednisone | Prednisone | 65 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 18 |
| Temazepam | Temazepam | 61 | 13 |
| Valacyclovir | Valacyclovir Hcl | 60 | 21 |
| Synthroid | Levothyroxine Sodium | 59 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 57 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | 12 |
| Trulicity | Dulaglutide | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 52 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 52 | 20 |
| Xarelto | Rivaroxaban | 52 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 11 |
| Lorazepam | Lorazepam | 50 | 15 |
| Mupirocin | Mupirocin | 50 | 26 |
| Alendronate Sodium | Alendronate Sodium | 49 | 17 |
| Potassium Chloride | Potassium Chloride | 48 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 47 | suppressed |
| Methylprednisolone | Methylprednisolone | 47 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 14 |
| Azithromycin | Azithromycin | 45 | 36 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 45 | 17 |
| Meloxicam | Meloxicam | 44 | 20 |
| Lovastatin | Lovastatin | 43 | 12 |
| Spironolactone | Spironolactone | 42 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Glipizide | Glipizide | 40 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 40 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 32 |
| Acyclovir | Acyclovir | 38 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Telmisartan | Telmisartan | 38 | suppressed |
| Nifedipine Er | Nifedipine | 37 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 13 |
| Celecoxib | Celecoxib | 35 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 22 |
| Mirtazapine | Mirtazapine | 32 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 11 |
| Estradiol | Estradiol | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 15 |
| Irbesartan | Irbesartan | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 13 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 11 |
| Nystatin | Nystatin | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,113.22 · 46 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, ELIQUIS, Exablate, FARXIGA, FREESTYLE LIBRE 3, GLYCATE, LEQEMBI, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, TRELEGY ELLIPTA, TZIELD, UBRELVY, YUPELRI, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error